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Abstract
Background: Hepatitis A virus (HAV), an atypical Picornaviridae that causes acute hepatitis in
humans, usurps the HAV cellular receptor 1 (HAVCR1) to infect cells. HAVCR1 is a class 1 integral
membrane glycoprotein that contains two extracellular domains: a virus-binding immunoglobulin-
like (IgV) domain and a mucin-like domain that extends the IgV from the cell membrane. Soluble
forms of HAVCR1 bind, alter, and neutralize cell culture-adapted HAV, which is attenuated for
humans. However, the requirements of the HAV-HAVCR1 interaction have not been fully
characterized, and it has not been determined whether HAVCR1 also serves as a receptor for wild-
type (wt) HAV. Here, we used HAV soluble receptor neutralization and alteration assays to study
the requirements of the HAV-HAVCR1 interaction and to determine whether HAVCR1 is also a
receptor for wt HAV.
Results: Treatment of HAV with a soluble form of HAVCR1 that contained the IgV and two-thirds
of the mucin domain fused to the Fc fragment of human IgG1 (D1 muc-Fc), altered particles at 37°C
but left a residual level of unaltered particles at 4°C. The kinetics of neutralization of HAV by D1
muc-Fc was faster at 37°C than at 4°C. Alteration of HAV particles by D1 muc-Fc required Ca,
which could not be replaced by Li, Na, Mg, Mn, or Zn. Neutralization of HAV by D1 muc-Fc
occurred at pH 5 to 8 but was more efficient at pH 6 to 7. D1 muc-Fc neutralized wt HAV as
determined by a cell culture system that allows the growth of wt HAV.
Conclusion: The interaction of HAV with soluble forms of HAVCR1 shares the temperature, Ca,
and pH requirements for infectivity in cell culture and therefore mimics the cell entry process of
HAV. Since soluble forms of HAVCR1 also neutralized wt HAV, this receptor may play a significant
role in pathogenesis of HAV.
Background
Hepatitis A virus (HAV), a Picornaviridae that causes acute
hepatitis in humans, has a positive sense RNA genome of
approximately 7.5 kb encapsidated in a shell formed by
60 copies of at least three viral proteins, VP1, VP2, and
VP3 [1]. A small unmyristoylated VP4 of 23 amino acids
is needed for capsid assembly [2] but has not been
detected in mature virions. Nonstructural protein 2A
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remains associated with the structural proteins and serves
as a signal for the assembly of pentamers, which are pre-
cursors involved in the morphogenesis of the capsid [2].
The cell entry mechanism of HAV is poorly understood
and cannot be inferred from other picornaviruses due to
its atypical characteristics and the diverse entry modes
used by other members of the family. HAV infects African
green monkey kidney cells via the hepatitis A cellular
receptor 1 (HAVCR1) [3]. The ectodomain of HAVCR1
contains an N-terminal immunoglobulin-like (Ig-like)
region (IgV), followed by an O-glycosylated threonine,
serine, and proline-rich mucin-like region that extends the
IgV well above the cell surface. The monkey and human
HAVCR1 share 79% homology and have HAV-receptor
function [3,4]. HAVCR1 is a costimulatory receptor in T
cells and has been implicated as an asthma determinant
[5,6]. HAV infection has a protective effect in the develop-
ment of allergy and asthma [7,8] but the role of HAVCR1
in this protective affect is not well understood and will
require a detailed analysis of the virus-receptor interac-
tion. We have previously shown that the IgV domain of
HAVCR1 is necessary for HAV receptor function [9] and
that the IgV and mucin domains are required to induce
conformational changes leading to the uncoating of HAV
[10]. Some of the requirements for the interaction of HAV
with cells were defined by experiments of classical virol-
ogy [11,12]. However, the development of a comprehen-
sive cell entry model for HAV will require further
investigation. In this paper, we study the influence of tem-
perature, cations, and pH in the interaction of HAV with
soluble HAVCR1 and found that it shares the physiologi-
cal requirements for infectivity in cell culture. Here, we
also showed that wild-type (wt) HAV interacts with
HAVCR1, which suggested that this receptor may play a
critical role in pathogenesis of HAV.
Results
Soluble HAVCR1 neutralized HAV at 4 and 37°C
We previously showed that D1 muc-Fc (Figure 1), a Fc
fusion protein containing the IgV and two-thirds of the
mucin-like regions of HAVCR1, bound and altered HAV
particles [13]. PVR-Fc, a similar Fc fusion protein contain-
ing the ectodomain of the poliovirus receptor PVR, did
not interact with HAV [13]. To study the effect of temper-
ature on the virus-receptor interaction, we treated HAV
particles with D1 muc-Fc or PVR-Fc at 4°C or 37°C and
analyzed their sedimentation profile in 15-30% sucrose
gradients. After ultracentrifugation at 40,000 rpm in an
SW40 rotor for 100 min at 4°C, we collected fractions
from the bottom of the gradients and determined the sed-
imentation profile of the HAV particles by ELISA using
anti-HAV antibodies [10]. Poliovirus virions (160S) and
empty particles (80S) labeled in vivo with 35S-methionine
were run in parallel gradients as sedimentation markers.
Treatment of HAV with D1 muc-Fc at both temperatures
altered the particles (Figure 2) whereas treatment with
PVR-Fc did not affect the sedimentation of the virions. A
residual level of virions treated with D1 muc-Fc at 4°C
remained unaltered, which suggested that HAV-HAVCR1
interaction at this low temperature was less efficient than
at 37°C. To further evaluate the effect of temperature in
the virus-receptor interaction, we analyzed the kinetics of
neutralization of HAV by D1 muc-Fc at 4°C or 37°C using
an ELISA endpoint dilution assay in 96-well plates con-
taining AGMK GL37 cells. Briefly, 106 TCID50 of HAV were
incubated at 4°C or 37°C with 20 μg of D1 muc-Fc or
PVR-Fc and the reduction in the HAV titers was evaluated
at different incubation times. Figure 3 shows that the
kinetics of neutralization was faster at 37°C than at 4°C,
and that viral titers were significantly lower after 5 min of
incubation at 37°C than at 4°C (p < 0.05). At 37°C, D1
muc-Fc neutralized approximately 1.3 log of HAV during
the first 15 min of incubation. The rate of neutralization
diminished dramatically after 15 min, with an additional
0.5 log of HAV neutralized after 2 h incubation. At 4°C,
the HAV titers remained stable during the first 15 min
incubation and then decreased slowly about 1 log in the
following 45 min. HAV neutralization did not increase
significantly between 1 h and 2 h incubation (p > 0.05),
but viral titers were about 0.5 log lower at 37°C than at
4°C. As expected, treatment with negative control PVR-Fc
Schematic representation of Fc fusion proteins Figure 1
Schematic representation of Fc fusion proteins. 
D1muc-Fc is a soluble form of HAVCR1 containing the IgV 
and two-thirds of the mucin-like domain of HAVCR1 fused 
to the hinge and Fc regions of human IgG1. A FLAG tag con-
sisting of 8 amino acid residues was introduced between the 
HAVCR1 and hinge portions. PVR-Fc, a soluble receptor 
form containing the whole ectodomain of the poliovirus 
receptor fused to the same hinge and Fc fragment of human 
IgG1 was used as a negative control fusion protein. Con-
struction and purification of D1muc-Fc and PVR-Fc was done 
as described [17].Virology Journal 2009, 6:175 http://www.virologyj.com/content/6/1/175
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at 4°C or 37°C did not affect the HAV titers (data not
shown). These data showed a dramatic difference in the
kinetics of interaction of HAV with HAVCR1 at 4°C and
37°C and indicated that the virus-receptor interaction is
faster and more efficient at physiological temperature.
Alteration of HAV by D1 muc-Fc is a calcium-dependent 
process
Since attachment and infectivity of HAV in cell culture is
a Ca-dependent process [12,14,15], we analyzed the cat-
ion requirement of the interaction of HAV with soluble
forms of HAVCR1. Purified HAV virions were treated with
D1 muc-Fc for 2 h at 37°C in the presence of 1 mM CaCl2,
10 mM MgCl2, 0.1 mM ZnCl2, 0.1 μM MnCl2, 500 mM
NaCl, or 10 mM LiCl and in the absence of any cations.
The effect of the different treatments was studied by sedi-
mentation in sucrose gradients. HAV particles were altered
only in the presence of CaCl2 (Figure 4), which mimics the
divalent cation requirement for infectivity of HAV in cell
culture. In the absence of D1 muc-Fc, treatment with 1
mM CaCl2 did not alter HAV particles showing that the
virions were stable at this concentration of Ca ions (data
not shown). To further confirm the Ca dependency, we
tested the effect of the Ca chelating agent ethylene glycol
bis(beta-aminoethyl ether)-N, N, N', N'-tetraacetic acid
(EGTA) in the alteration of the HAV particles. Purified
HAV particles were treated with 5 μg of D1 muc-Fc or con-
trol PVR-Fc in a buffer containing 1 mM CaCl2 in the pres-
ence or absence of 2 mM EGTA. After 2 h incubation at
37°C, the HAV particles were analyzed by sedimentation
in 15 to 30% sucrose gradients (Figure 5). The sedimenta-
tion profiles revealed that the EGTA treatment inhibited
the alteration of the HAV particles. Treatment of HAV with
PVR-Fc in the presence of EGTA did not affect the sedi-
mentation of the virions, which indicated that EGTA did
not affect the stability of the HAV particles. Our results
clearly showed that the alteration of HAV particles by D1
muc-Fc required the presence of Ca ions.
The HAV-HAVCR1 interaction is optimal at neutral pH
To analyze the pH requirements for the virus-receptor
interaction, HAV (105 TCID50) was treated overnight with
20 μg of purified D1 muc-Fc or control PVR-Fc at pH 5, 6,
7 or 8, and residual HAV infectivity was titrated by an
ELISA endpoint dilution assay (Figure 6). D1 muc-Fc neu-
tralized HAV at all pHs but maximum levels of neutraliza-
tion were achieved at pH 6-7. Treatment of HAV with
PVR-Fc at the different pHs did not significantly affect the
viral titers, which showed that HAV was stable at these
experimental conditions. Therefore, D1 muc-Fc neutral-
ized HAV in a wide pH range (from 5 to 8) with an opti-
mal interaction at pH 7.
Neutralization of wt HAV by soluble HAVCR1
Cell culture-adapted strains of HAV are attenuated for
humans and contain several mutations, including at least
two located in the viral capsid proteins VP1 and VP2. We
have shown that soluble HAVCR1 neutralize the cell cul-
ture-adapted strain HM175 of HAV [16,17]. To analyze
whether HAVCR1 could also interact with wt HAV, we
neutralized a wt HAV construct containing a blasticidin
selectable marker (HAV.WT-Bsd) [18] with soluble D1
muc-Fc. Briefly, HAV.WT-Bsd (105TCID50) was treated
with 20 μg of D1 muc-Fc or PVR-Fc for 2 h at 37°C, and
residual infectious virus was titrated in 96-well plates con-
taining 20-50% confluent monolayers of Huh-7-A-I cells
in the presence of 2 μg/ml blasticidin. At 7 days postinfec-
tion, viral titers were determined by assessing the presence
of blasticidin-resistant surviving cells in replica wells [19].
Figure 7 shows that D1 muc-Fc neutralized approximately
1 log of HAV.WT-Bsd (NI = 0.79) whereas control PVR-Fc
had almost no effect in the viral titer (NI = 0.003). This
very significant reduction in infectivity (p < 0.01) indi-
Effect of temperature in the alteration of HAV by soluble  HAVCR1 Figure 2
Effect of temperature in the alteration of HAV by 
soluble HAVCR1. Sedimentation analysis of HAV particles 
treated with soluble receptors at different temperatures. 
Purified HAV virions were incubated with 20 μg of D1 muc-
Fc or control PVR-Fc for 30 min at 4°C or 37°C, loaded 
onto linear 15 to 30% sucrose gradients, and ultracentri-
fuged. The gradient was collected from the bottom in 20 
fractions, and HAV antigen in the fractions was determined 
by ELISA [17]. The first 15 fractions of each gradient are 
shown. Data are mean results from duplicate wells; duplicate 
values varied by less than 10%. Poliovirus native virions and 
empty particles labeled with 35S-methionine were used as 
160S and 80S sedimentation markers. The top and bottom of 
the gradients are indicated.
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cated that HAVCR1 also functions as a receptor for wt
HAV. Treatment of cell culture adapted HAV with D1
muc-Fc under the same conditions also reduced infectivity
approximately 1 log (NI = 0.94) whereas PVR-Fc had
almost no effect (NI = 0.02), which indicated that
HAVCR1 interacted efficiently with wt HAV.
Discussion
We have previously determined that the IgV domain of
HAVCR1 is required for HAV-receptor function [9,16]. We
also showed that the IgV and the mucin-like regions are
needed to induce conformational changes leading to the
uncoating of HAV particles [17]. To further characterize
how HAV interacts with HAVCR1, we evaluated the tem-
perature, cation, and pH requirements of the HAVCR1-
mediated alteration and neutralization of HAV. Soluble
HAVCR1 neutralized HAV at 37°C and 4°C but with sig-
nificantly different kinetics (Figure 3). Our data are con-
sistent with previous studies showing a faster kinetics of
HAV binding and infection at 37°C than at 4°C [20-22].
The difference in the neutralization kinetics at 37°C and
4°C indicated that the neutralization reaction followed
different mechanisms. At 37°C, the neutralization reac-
tion followed a one-hit kinetics, in which only one or few
receptor molecules per particle were needed to neutralize
the virus [23,24]. At 4°C, it most likely followed a multi-
hit kinetics, in which D1 muc-Fc bound slowly to HAV
covering the particles and triggering neutralization after
saturation of the binding sites. Alternatively, binding of
the soluble receptors at 4°C may induce the slow diffu-
sion of a putative stabilizing factor that triggered the
destabilization of the viral particles.
Our studies showed that the alteration of HAV by soluble
HAVCR1 is a Ca-dependent process (Figure 4 and 5),
which is consistent with previously published reports
showing that binding of HAV to cells and infection is
enhanced by Ca ions [20-22]. Calcium plays an important
role at different levels of the cell entry process of viruses
[25]. Since Ca is required for the HAV-HAVCR1 interac-
tion, it is possible that Ca ions enhance binding of HAV to
HAVCR1 and allow the alteration of the viral particles, a
process required to deliver the virus genome into the cyto-
plasm. It has been previously shown that Ca can slowly
destabilize the HAV particles [20-22], so Ca ions could be
required to alter the virions after binding to HAVCR1.
Alternatively, the mucin-like domain of HAVCR1 may
require calcium ions for the proper presentation of the IgV
Effect of temperature in the neutralization of HAV by soluble HAVCR1 Figure 3
Effect of temperature in the neutralization of HAV by soluble HAVCR1. Kinetics of neutralization of cell culture-
adapted HAV by soluble HAVCR1 at different temperatures. HAV(106 TCID50) was incubated with 20 μg of purified D1 muc-
Fc or control PVR-Fc, for different times at 4°C and 37°C. After incubation, neutralization reactions were diluted 1/100 and 
residual infectious HAV was titrated by an ELISA end point dilution assay in 96-well plates containing confluent monolayers of 
GL37 cells. Values are the log10 TCID50/ml of HAV determined by the Reed and Muench method [30] and the standard devia-
tions are shown as error bars. Significant differences (P < 0.05) in viral titers at 37°C and 4°C for each time point are indicated 
with asterisks and their corresponding p-values.
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domain to allow virus binding and/or alteration. Further
research will be required to understand the exact role of
Ca ions in the HAV-HAVCR1 interaction.
Soluble HAVCR1 neutralized HAV at pH 5 to 8 but the
reaction proceeded more efficiently at neutral pH (Figure
6). HAV is transmitted through the fecal-oral route, so the
ability of HAV to interact with HAVCR1 in a wide pH
range suggested that HAVCR1 could mediate infection of
cells in the gastrointestinal track. The ability of HAVCR1
to interact with HAV at different pHs may also have a role
in the cell entry process of HAV. Although the uncoating
site of HAV is not know, the efficient virus-receptor inter-
action at low pH also suggested that HAV could be inter-
nalized to a low pH endocytic compartment prior to
delivery of the RNA genome to the cytoplasm. Since low
pH enhanced attachment HAV to BS-C1 cells [20] and red
blood cells [26] but did not increase neutralization by sol-
uble HAVCR1, it is possible that at low pH the virus parti-
cles expose additional epitopes or enhanced binding sites
that allow attachment to other receptors at the cell surface.
The role of HAVCR1 in pathogenesis of HAV has been dif-
ficult to determine due to the lack of a small animal
model for HAV. HAVCR1 was identified as a cellular
receptor for cell culture adapted strains of HAV [3,4] in
cell culture. Cell culture-adapted strains of HAV contain
several mutations that attenuate the virus and could
potentially change the receptor preference of the virus.
Our finding that soluble HAVCR1 neutralized wt HAV
suggested that this virus could use HAVCR1 to cause dis-
ease in humans.
Conclusion
Our results clearly show that the interaction of HAV with
soluble HAVCR1 mimics the cell entry process of HAV.
We previously showed that soluble forms of HAVCR1
altered the viral particles, a process required for uncoating
of the viral genome. Here, we determined that neutraliza-
Effect of monovalent and divalent cations in the alteration of  HAV by soluble HAVCR1 Figure 4
Effect of monovalent and divalent cations in the 
alteration of HAV by soluble HAVCR1. Sedimentation 
analysis of cell culture-adapted HAV treated with soluble 
HAVCR1 in the presence or absence of different cations. 
Purified HAV virions were incubated with 5 μg of D1 muc-Fc 
for 2 h at 37°C in the presence of 1 mM CaCl2, 10 mM 
MgCl2, 0.1 mM ZnCl2, 0.1 μM MnCl2, 500 mM NaCl, or 10 
mM LiCl and also in the absence of any cations, and sedi-
mented in linear 15 to 30% sucrose gradients as described in 
Figure 2. HAV antigen was detected by ELISA. The data are 
mean OD 450 nm from duplicate wells; duplicate values var-
ied by less than 10%. Poliovirus native virions and empty par-
ticles labeled with 35S-methionine were used as 160S and 80S 
sedimentation markers.
EGTA inhibits the alteration of HAV by soluble HAVCR1 Figure 5
EGTA inhibits the alteration of HAV by soluble 
HAVCR1. Sedimentation analysis of HAV alteration by solu-
ble HAVCR1 in the presence of ethylene glycol bis(beta-ami-
noethyl ether)-N, N, N', N'-tetraacetic acid (EGTA). Purified 
HAV virions were incubated with 5 μg of D1 muc-Fc or PVR-
Fc for 2 h at 37°C with or without the addition of EGTA and 
separated by sedimentation in linear 15 to 30% sucrose gra-
dients as described in Figure 2. The HAV antigen in the gradi-
ent fractions was detected by ELISA. Data are the mean OD 
450 nm from duplicate wells; duplicate values varied by less 
than 10%. Poliovirus native virions and empty particles 
labeled with 35S-methionine were used as 160S and 80S sedi-
mentation markers.Virology Journal 2009, 6:175 http://www.virologyj.com/content/6/1/175
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tion and alteration of HAV by soluble HAVCR1 is a Ca-
dependent process that is optimum at 37°C and occurs at
pH 5 to 8, which are known requirements for HAV infec-
tivity in cell culture. We also showed that HAVCR1 could
function as cellular receptors for wt HAV since treatment
with soluble receptors neutralized the virus. Taken
together, our data suggested that HAVCR1 may play a sig-
nificant role in pathogenesis of HAV.
Methods
Antisera
Anti-HAV serum was produced in rabbits immunized
with commercially available HAV vaccine [16]. Phos-
phatase-labeled goat anti-rabbit IgG antibody was used as
suggested by the manufacturer (Kirkegaard & Perry Labo-
ratories, Inc.).
Cells and viruses
The continuous clone GL37 of African green monkey kid-
ney (AGMK GL37) cells [27] was grown in Eagle's mini-
mal essential medium (EMEM) containing 10% heat-
inactivated fetal bovine serum (FBS).
Chinese hamster ovary (CHO) cell transfectants express-
ing Fc fusion proteins of HAVCR1 or the poliovirus recep-
tor (PVR) were grown in Iscove's medium containing 10%
dialyzed FBS and 5 mM methotrexate (MP Biochemicals)
as described [16].
Huh-7-A-I cells, a clone of human hepatoma Huh-7 cells
that allowed the stable growth of wt HAV [18], was grown
in Dulbecco's modified minimal essential medium
(DMEM) supplemented with 10% heat-inactivated FBS.
The cell culture-adapted strain HM175 of HAV was
derived from infectious cDNA [28] and passed approxi-
mately 100 times in the continuous BSC-1 cell line of Afri-
can green monkey kidney. Virus stocks were prepared by
growing HAV in fetal Rhesus kidney (FRhK-4) cells for 10
days. Infected monolayers and culture supernatants were
subjected to three freeze-and-thaw cycles, clarified by cen-
trifugation, and stored at -70°C.
Purified HAV was produced in FRhK4 cells infected with a
cytopathic variant of cell culture-adapted strain HM175 of
HAV [29].
Effect of pH on soluble HAVCR1-mediated neutralization of  HAV Figure 6
Effect of pH on soluble HAVCR1-mediated neutrali-
zation of HAV. HAV PI (105 TCID50) was incubated with 
20 μg of purified D1 muc-Fc (hatched bars) or control PVR-
Fc (closed bars) in EMEM at pH 5, 6, 7, or 8 overnight at 4°C. 
Residual infectious HAV was titrated by an ELISA end point 
dilution assay. Values are the log10 TCID50 HAV determined 
by the Reed and Muench method [30] and the standard devi-
ations are shown as error bars. Significant differences (p < 
0.05) in titers of virus treated with D1 muc-Fc or PVR-Fc at 
each pH are indicated with asterisks and their corresponding 
p-values.
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Neutralization of wild-type HAV by soluble HAVCR1 Figure 7
Neutralization of wild-type HAV by soluble 
HAVCR1. HAV.WT-Bsd (5 × 105 TCID50), a wild-type HAV 
recombinant virus containing a blasticidin selectable marker, 
or cell culture-adapted HAV (5 × 106TCID50) were incu-
bated with 20 μg of D1 muc-Fc (hatched bars) or PVR-Fc 
(closed bars) for 2 h at 37°C. Residual infectious wt HAV 
virus was titrated by the antibiotic resistance titration assay 
(ARTA) in Huh-7 AI in the presence of 2 μg/ml blasticidin. 
Residual infectious cell culture-adapted HAV was titrated by 
an ELISA end point dilution assay [16]. Values are the log10 
TCID50 of HAV determined by the Reed and Muench 
method [30], and the standard deviations are shown as error 
bars. The neutralization index (NI) of soluble receptor-
treated virus compared to mock-treated virus is indicated 
above each bar. Very significant differences (p < 0.01) in tit-
ers of virus treated with D1 muc-Fc or PVR-Fc are indicated 
with asterisks and their corresponding p-values.
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A wt HAV construct containing a blasticidin selectable
marker cloned at the 2A-2B junction of wt HAV genome
(HAV.WT-Bsd) was grown in Huh-7-A-I cells [18].
HAV titer determination
Cell culture-adapted HAV was titrated by an endpoint
dilution assay in 96-well plates containing confluent
monolayers of AGMK GL37 cells [16]. Briefly, 8 to 16 rep-
licate wells were inoculated with 100 μl each of 10-fold
dilutions of HAV and grown at 35°C for 2 weeks in a CO2
incubator. Cells were fixed with 95% methanol, and HAV
was detected by ELISA staining with rabbit anti-HAV anti-
body and peroxidase-labeled goat anti-rabbit antibody.
Wells that developed at least 2.5 times the color of unin-
fected control wells were considered positive, and viral tit-
ers were calculated by the Reed and Muench method [30].
HAV.WT-Bsd was titrated using an antibiotic-resistance
titration assay (ARTA) [19] based on the endpoint dilu-
tion of the virus in 96-well plates containing 20-50% con-
fluent monolayers of Huh-7-A-I cells and the selection of
antibiotic-resistant infected cells in the presence of 2 μg/
ml blasticidin. Five to seven days after infection, the 96-
well plates were examined under the microscope to deter-
mine the presence of live cells. Viral titers were deter-
mined using the Reed and Muench method [30]. The
neutralization index (NI) was calculated with the formula
NI = log (TCID50 mock-treated virus sample) - log(TCID50
receptor-treated virus sample) [31].
Neutralization assays
HAV was neutralized with a purified recombinant pro-
teins containing the IgV domain and 2/3 of the mucin-like
region of HAVCR1 fused to the hinge and Fc portions of
human IgG1 (D1 muc-Fc) [17]. A recombinant protein
containing the ectodomain of PVR fused to the same Fc
fragment (PVR-Fc) was used as a negative neutralization
control [17].
To evaluate the effect of temperature in the virus -receptor
interaction, cell culture-adapted HAV (5 × 106 TCID50)
was incubated at 4°C or 37°C with 20 μg of D1 muc-Fc or
PVR-Fc. Aliquots of the neutralization reaction were taken
at different times after incubation. Samples were diluted
1/100 in cell culture media and residual infectious virus
was titrated in 96-well plates containing confluent mon-
olayers of the AGMK GL37 cells. The virus was inoculated
in 8 to16 wells/dilution and adsorbed for 4 h at 37°C in
a CO2 incubator. After washing three times with EMEM
(to remove unbound virus), 200 μl/well of EMEM-10%
FBS was added and the plates were incubated at 35°C
under CO2 for 14 days, and HAV titers were determined by
ELISA.
To neutralize HAV.WT-Bsd, 20 μg of D1 muc-Fc or PVR-Fc
were incubated with 5 × 105 TCID50 of virus for 2 h at
37°C. Neutralization reactions were diluted 1/100 and
residual infectious virus was titrated by ARTA in 96-well
plates containing 20-50% confluent monolayers of Huh-
7-AI cells. Viral titers were determined seven days after
infection [18].
Sedimentation analysis of HAV particles
HAV virions were purified by sedimentation in linear 15
to 30% sucrose gradients with a Beckman SW40 rotor at
4°C for 100 min at 40,000 rpm. Gradients were collected
from the bottom in 20 fractions of 0.5 ml each, and HAV
was detected by ELISA [16]. The 160S virion peak was
pooled and stored at -70°C.
To study the effect of temperature in the alteration of
HAV, sucrose-purified virions were treated with 20 μg of
PVR-Fc or D1 muc-Fc for two hours at 4°C or 37°C, and
analyzed by ultracentrifugation in 15 to 30% sucrose gra-
dients as indicated above. To determine the requirement
of monovalent or divalent cations for the alteration of
HAV by soluble receptors, sucrose-purified virions were
treated with 5 μg of PVR-Fc or D1 muc-Fc for 2 h at 4°C
in the presence of 1 mM CaCl2, 10 mM MgCl2, 0.1 mM
ZnCl2, 0.1 mM MnCl2, 500 mM NaCl or 10 mM LiCl. The
sedimentation profile of HAV was analyzed by ultracen-
trifugation in 15 to 30% sucrose gradients as indicated
above. 35S-labeled poliovirus [32] was used as a sedimen-
tation marker, and 160S virions and 80S empty particles
were identified by scintillation counting.
Statistical analysis
Viral titers and standard deviations were determined by
the Reed and Muench [30] method and calculated with
the ID50 program developed by John L. Spouge (National
Center for Biotechnology Information, NIH). Statistical
significance between two viral titers was determined by
the unpaired Student's t-test an calculated using Graph
Pad software, and p-values were included in the text and
figures.
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